Edgewise Therapeutics (NASDAQ:EWTX) received an updated price target from JPMorgan, with analysts at the firm raising their ...

JPMorgan analyst Tessa Romero placed shares of Edgewise Therapeutics (EWTX) on “Positive Catalyst Watch” while keeping an Overweight rating on ...

JPMorgan analyst Tessa Romero placed shares of Edgewise Therapeutics (EWTX) on “Positive Catalyst Watch” while keeping an Overweight rating on ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

- Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) - - Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Edgewise ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment with a market capitalization of $2.6 billion, today announced significant ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen's other long-term stock picks. Andreas Halvorsen is a prominent ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...